Haynes & Boone Advises Pulmatrix on Strategic Merger to Advance Biotech Innovation
November 14, 2024
November 14, 2024
DALLAS, Texas, Nov. 14 -- Haynes and Boone, a law firm, issued the following news release:
Haynes Boone served as legal counsel to Pulmatrix, Inc. (Nasdaq: PULM), a clinical-stage biopharmaceutical company, in its proposed merger with Cullgen, Inc., a privately held biotechnology company pioneering targeted protein degradation technologies.
The combined entity will focus on advancing Cullgen's clinical programs targeting cancer and chronic pain, creating a Nasdaq-liste . . .
Haynes Boone served as legal counsel to Pulmatrix, Inc. (Nasdaq: PULM), a clinical-stage biopharmaceutical company, in its proposed merger with Cullgen, Inc., a privately held biotechnology company pioneering targeted protein degradation technologies.
The combined entity will focus on advancing Cullgen's clinical programs targeting cancer and chronic pain, creating a Nasdaq-liste . . .